Chemoprevention of squamous cell carcinoma of the oral cavity

Otolaryngologic Clinics of North America

Volumn 39, Issue 2, 2006, Pages 349-363

  Brown, Kevin S ^a   Kane, Madeleine A ^b  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 PHENYLENEBIS(METHYLENE)SELENOCYANATE; ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CELECOXIB; CYCLIN D1; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETRETINATE; FLAVONOID; FOLIC ACID; GAMMA TOCOPHEROL; HERBACEOUS AGENT; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; ONYX 015; PELITINIB; PLANT EXTRACT; RETINOID; RETINOL; SELENIUM; SELENIUM DERIVATIVE; SELENODIGLUTATHIONE; TAMOXIFEN; TRACE ELEMENT; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ALCOHOL CONSUMPTION; BETEL NUT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CARCINOGENESIS; CHEILITIS; CLINICAL TRIAL; COLON POLYP; COLORECTAL CANCER; DNA METHYLATION; DRY SKIN; FACE ERYTHEMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; LARYNX CANCER; LARYNX DISORDER; LEUKOPLAKIA; LUNG CANCER; MASTICATION; MORBIDITY; MORTALITY; MOUTH CANCER; MOUTH CARCINOMA; MOUTH INTRAEPITHELIAL NEOPLASIA; NEURAL TUBE DEFECT; NONHUMAN; OROPHARYNX CANCER; PHARYNX CANCER; PRECANCER; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; SPIRULINA; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRUS CARCINOGENESIS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WART VIRUS;

ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CARCINOMA, SQUAMOUS CELL; DRUGS, CHINESE HERBAL; FLAVONOIDS; FOLIC ACID; HUMANS; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; RETINOIDS; SELENIUM; VITAMIN A; VITAMIN E;

EID: 33645881076     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2005.11.010     Document Type: Review

References (82)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer Statistics, 2004. CA Cancer J Clin 54 1 (2004) 8-29
2. Jeng J.H., Chang M.C., and Hahn L.J. Role of areca nut in betal quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol 37 6 (2001) 477-492
3. Braakhuis B.J.M., Snijders P.J.F., Keune W.-J.H., et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 96 13 (2004) 998-1006
4. Mao L., and Hong W.K. How does human papillomavirus contribute to head and neck cancer development?. J Natl Cancer Inst 96 13 (2004) 978-980
5. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 18 (1998) 1361-1370
6. Thun M.J., Namboodiri M.M., and Heath C.W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325 23 (1991) 1593-1596
7. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 26 (2000) 1946-1952
8. Jaloszynski P., Jaruga P., Olinski R., et al. Oxidative DNA base modifications and polycyclic aromatic hydrocarbon DNA adducts in squamous cell carcinoma of larynx. Free Radic Res 37 3 (2003) 231-240
9. Dannenberg A.J., Lippman S.M., Mann J.R., et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23 2 (2005) 254-266
10. Lippman S.M., Sudbo J., and Hong W.K. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 23 2 (2005) 346-356
11. Mao L., Hong W.K., and Papadimitrakopoulou V.A. Focus on head and neck cancer. Cancer Cell 5 (2004) 311-316
12. Hasegawa M., Nelson H.H., Peters E., et al. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21 27 (2002) 4231-4236
13. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 21 (2003) 2042-2054
14. 2 gene in head and neck carcinogenesis. Clin Cancer Res 10 (2004) 1733-1742
15. Sen S. Aneuploidy and cancer. Curr Opin Oncol 12 1 (2000) 82-88
16. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 6712 (1998) 643-649
17. Gardner R.D., and Burke D.J. The spindle checkpoint: two transitions, two pathways. Trends Cell Biol 10 4 (2000) 154-158
18. Sudbo J., Kildal W., Risberg B., et al. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 344 17 (2001) 1270-1278
19. Sudbo J., Lippman S.M., Lee J.J., et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 350 14 (2004) 1405-1413
20. Zhang L., Poh C.F., Lam W.L., et al. Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection. Oral Oncol 37 6 (2001) 505-512
21. Betz C.S., and Leunig A. Potential and limitations of fluorescence diagnosis and photodynamic therapy part 2: photodynamic therapy. HNO 52 2 (2004) 175-192
22. Slaughter D.P., Southwick H.W., and Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 6 (1953) 963-968
23. Braakhuis B.J., Tabor M.P., Kummer J.A., et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63 8 (2003) 1727-1730
24. Murr G., Kostelic F., Donkic-Pavicic I., et al. Comparison of the vitamin A blood serum level in patients with head-neck cancer and healthy persons. HNO 36 9 (1988) 359-362
25. deVries N., and Snow G.B. Relationships of vitamins A and E and beta-carotene serum levels to head and neck cancer patients with and without second primary tumors. Eur Arch Otorhinolaryngol 247 6 (1990) 368-370
26. Hong W.K., Endicott J., Itri L.M., et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315 24 (1986) 1501-1505
27. Lotan R., Xu X.-C., Lippman S.M., et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 332 21 (1995) 1405-1411
28. Langenfeld J., Kiyokawa H., Sekula D., et al. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 94 22 (1997) 12070-12074
29. Hong W.K., Lippman S.M., Itri L.M., et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323 12 (1990) 795-801
30. Lippman S.M., Batsakis J.G., Toth B.B., et al. Comparison of low-dose isotretinoin with beta-carotene to prevent oral carcinogenesis. N Engl J Med 328 1 (1993) 15-20
31. van Zandwijk N., Dalesio O., Pastorino U., et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst 92 12 (2000) 977-986
32. Bolla M., Lefur R., Van J.T., et al. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer 30 6 (1994) 767-772
33. Omenn G.S., Goodman G.E., Thornquist M.D., et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334 18 (1996) 1150-1155
34. Cartmel B., Moon T.E., and Levine N. Effects of long-term intake of retinol on selected clinical and laboratory indexes. Am J Clin Nutr 69 5 (1999) 937-943
35. Perry C.F., Stevens M., Rabie I., et al. Chemoprevention of head and neck cancer with retinoids: a negative result. Arch Otolaryngol Head Neck Surg 131 3 (2005) 198-203
36. Lingen M.W., Polverini P.J., and Bouck N.P. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 58 23 (1998) 5551-5558
37. Lindner D.J., Borden E.C., and Kalvakolanu D.V. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res 3 6 (1997) 931-937
38. Lippman S.M., Parkinson D.R., Itri L.M., et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84 4 (1992) 235-241
39. Lippman S.M., Kavanagh J.J., Paredes-Espinoza M.P., et al. 13-cis retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 85 6 (1993) 499-500
40. Motzer R.J., Schwartz L., Law T.M., et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13 8 (1995) 1950-1957
41. Shin D.M., Mao L., Papadimitrakopoulou V.M., et al. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst 92 1 (2000) 69-73
42. Shin DM, Richards TJ, Seixas-Silva JA, et al., Phase II trial of bioadjuvant therapy with interferon-alpha2a, 13-cis-retinoic acid, and alpha-tocopherol for locally advanced squamous cell carcinoma of the head and neck: long term follow-up [Abstract 1995]. In: Proceeding of the American Society of Clinical Oncology. Chicago: 2003. p. 496.
43. Zheng W., Blot W.J., Diamond E.L., et al. Serum micronutrients and the subsequent risk of oral and pharyngeal cancer. Cancer Res 53 4 (1993) 795-798
44. Leo M.A., Seitz H.K., Maier H., et al. Carotenoid, retinoid and vitamin E status of the oropharyngeal mucosa in the alcoholic. Alcohol Alcohol 30 2 (1995) 163-170
45. Negri E., Franceschi S., Bosetti C., et al. Selected micronutrients and oral and pharyngeal cancer. Int J Cancer 86 1 (2000) 122-127
46. Garewal H.S., Meyskens Jr. F.L., Killen D., et al. Response of oral leukoplakia to beta-carotene. J Clin Oncol 8 10 (1990) 1715-1720
47. Mayne S.T., Cartmel B., Baum M., et al. Randomized trial of supplemental beta-carotene to prevent second head and neck cancer. Cancer Res 61 4 (2001) 1457-1463
48. Hennekens C.H., Buring J.E., Manson J.E., et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334 18 (1996) 1145-1149
49. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330 15 (1994) 1029-1035
50. Trickler D., and Shklar G. Prevention by vitamin E of experimental oral carcinogenesis. J Natl Cancer Inst 78 1 (1987) 165-169
51. Calhoun K.H., Stanley D., Stiernberg C.M., et al. Vitamins A and E do protect against oral carcinomas. Arch Otolaryngol Head Neck Surg 115 4 (1989) 484-488
52. Sawant S.S., and Kandarkar S.V. Role of vitamins C and E as chemopreventive agents in the hamster cheek pouch treated with the oral carcinogen DMBA. Oral Dis 6 (2000) 241-247
53. Gridley G., McLaughlin J.K., Block G., et al. Vitamin supplement use and reduced risk of oral and pharyngeal cancer. Am J Epidemiol 135 10 (1992) 1083-1092
54. Steward D.L., Wiener F., Gleich L.L., et al. Dietary antioxidant intake in patients at risk for secondary primary cancer. Laryngoscope 113 9 (2003) 1487-1493
55. Benner S.E., Winn R.J., Lippmann S.M., et al. Regression of oral leukoplakia with alpha-tocopherol: a community clinical oncology program chemoprevention study. J Natl Cancer Inst 85 1 (1993) 44-47
56. Bairati I., Meyer F., Gelinas M., et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 23 24 (2005) 5805-5813
57. Pauling L., Willoughby R., Reynolds R., et al. Int J Vitam Nutr Res Suppl 23 (1982) 53-82
58. Sakagami H., Satoh K., Hakeda Y., et al. Apoptosis-inducing activity of vitamin C and vitamin K. Cell Mol Biol 46 1 (2000) 129-143
59. Franceschi S., Bidoli E., Negri E., et al. Role of macronutrients, vitamins and minerals in the aetiology of squamous cell carcinoma of the oesophagus. Int J Cancer 86 5 (2000) 626-631
60. Almadori G., Bussu F., Galli J., et al. Serum folate and homocysteine levels in head and neck carcinoma. Cancer 94 4 (2002) 1006-1011
61. Almadori G., Bussu F., Galli J., et al. Serum levels of folate, homocysteine and vitamin B12 in head and neck squamous cell carcinoma and in laryngeal leukoplakia. Cancer 103 2 (2005) 284-292
62. Rampersaud G.C., Kauwell G.P.A., and Hutson A.D. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am J Nutr 72 (2000) 998-1003
63. Werler M.M., Shapiro S., and Mitchell A.A. Periconceptual folic acid exposure and risk of occurrent neural tube defects. JAMA 269 10 (1993) 1257-1261
64. Zhang Z., Shi Q., Sturgis E.M., et al. Thymidylate synthase 5′- and 3′- untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 10 23 (2004) 7903-7910
65. Kane M.A. The role of folates in squamous cell carcinoma of the head and neck. Cancer Detect Prev 29 1 (2005) 46-53
66. Goodwin Jr. W.J., Lane H.W., Bradford K., et al. Selenium and glutathione peroxidase levels in patients with epidermoid carcinoma of the oral cavity and oropharynx. Cancer 51 1 (1983) 110-115
67. Negri E., Franceschi S., Bosetti C., et al. Selected micronutrients and oral and pharyngeal cancer. Int J Cancer 86 1 (2000) 122-127
68. Ghose A., Fleming J., El-Bayoumy K., et al. Enhanced sensitivity of human oral carcinomas to induction of apoptosis by selenium compounds: involvement of mitogen-activated kinase and Fas pathways. Cancer Res 61 20 (2001) 7479-7487
69. Tanaka T., Makita H., Kawabata K., et al. 1,4-phenylenebis(methylene)selenocyanate exerts exceptional chemopreventive activity in rat tongue carcinogenesis. Cancer Res 57 (1997) 3644-3648
70. Schwartz J., and Shklar G. Regression of experimental hamster cancer by beta carotene and algae extracts. J Oral Maxillofac Surg 45 (1987) 510-515
71. Mathew B., Sankaranarayanan R., Nair P.P., et al. Evaluation of chemoprevention of oral cancer with Spirulina fusiformis. Nutr Cancer 24 (1995) 197-202
72. Casto B.C., Kresty L.A., Kraly C.L., et al. Chemoprevention of oral cancer by black raspberries. Anticancer Res 22 (2002) 4005-4015
73. Grandis J.R., and Tweardy D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53 15 (1993) 3579-3584
74. Shin D.M., Ro J.Y., Hong W.K., et al. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54 12 (1994) 3153-3159
75. Subbaramaiah K., Altorki N., Chung W.J., et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274 16 (1999) 10911-10915
76. Dannenberg A.J., Altorki N.K., Boyle J.O., et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2 9 (2001) 544-551
77. Pai R., Soreghan B., Szabo I.L., et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8 3 (2002) 289-293
78. Buchanan F.G., Wang D., Bargiacchi F., et al. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278 37 (2003) 35451-35457
79. Torrance C.J., Jackson P.E., Montgomery E., et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6 9 (2000) 1024-1028
80. Ries S., and Korn W.M. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 86 1 (2002) 5-11
81. Heise C., Sampson-Johannes A., Williams A., et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3 6 (1997) 639-645
82. Rudin C.M., Cohen E.E., Papadimitrakopoulou V.A., et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21 24 (2003) 4546-4552